The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine

[1]  Margot Albus,et al.  Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[2]  T. Someya,et al.  Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine , 2004, European Journal of Clinical Pharmacology.

[3]  R. Kaiser,et al.  Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. , 2004, Pharmacogenetics.

[4]  A. Schatzberg,et al.  Pharmacogenetics of antidepressant medication intolerance. , 2003, The American journal of psychiatry.

[5]  R. Kaiser,et al.  Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Otani,et al.  Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients , 2003, Psychopharmacology.

[7]  B. Gutiérrez,et al.  Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response , 2002, Schizophrenia Research.

[8]  M. Morales,et al.  Differential Composition of 5-Hydroxytryptamine3Receptors Synthesized in the Rat CNS and Peripheral Nervous System , 2002, The Journal of Neuroscience.

[9]  M. Cazzola,et al.  A novel deletion of the l‐ferritin iron‐responsive element responsible for severe hereditary hyperferritinaemia–cataract syndrome , 2002, British journal of haematology.

[10]  Y. Sawada,et al.  [Analysis of 5-HT3 receptor antagonist, ramosetron hydrochloride, based on receptor occupancy considering its active metabolite]. , 2001, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[11]  M. Rietschel,et al.  Association between the 5' UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. , 2001, Pharmacogenetics.

[12]  Trevor Sharp,et al.  A review of central 5-HT receptors and their function , 1999, Neuropharmacology.

[13]  D. Menon,et al.  Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[14]  O. Andreassen,et al.  Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. , 1995, Pharmacogenetics.

[15]  M. Ingelman-Sundberg,et al.  Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.

[16]  P. Blier,et al.  Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. , 1994, The American journal of psychiatry.

[17]  J. Hallas,et al.  The relationship between paroxetine and the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.

[18]  D. Stewart,et al.  Cancer therapy, vomiting, and antiemetics. , 1990, Canadian journal of physiology and pharmacology.

[19]  C. Kaye,et al.  A review of the metabolism and pharmacokinetics of paroxetine in man , 1989, Acta psychiatrica Scandinavica. Supplementum.

[20]  M. Tyers,et al.  Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists. , 1992, Oncology.

[21]  H. Möller,et al.  Comparative efficacy of antidepressants. Discussion , 1992 .

[22]  K. Bunce,et al.  Pharmacological and anti-emetic properties of ondansetron. , 1989, European journal of cancer & clinical oncology.